Nicotinic acid/laropiprant: a new lipid‐modifying therapy

Tredaptive is a combination of nicotinic acid and laropiprant for the treatment of dyslipidaemia and primary hypercholesterolaemia. In our New products review, Steve Chaplin discusses the clinical data relating to its efficacy and side‐effects, and Dr Marc Evans describes its place in therapy. Copyright © 2009 Wiley Interface Ltd